ClinicalTrials.gg
CompletedNCT04682639VOYAGEUpdated May 6, 2024Results posted

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

A Phase 2 interventional study of Etrasimod and Placebo in Eosinophilic Esophagitis, sponsored by Pfizer. Completed at 256 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-06.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 41 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.

Enrollment
20th of 111
108 · median 36
Started
2020
with 10 others
Phase 2
30 of 165
3 open now
Registered
117th of 165
by date

Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 20th largest by enrollment of the 111 interventional ones that give a count, is one of 11 that started in 2020, is one of 30 in phase 2, and was the 117th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Eosinophilic Esophagitis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.

03

Conditions studied

  • Eosinophilic Esophagitis

Keywords

  • Eosinophilic esophagitis
  • Esophageal eosinophilia
  • Etrasimod
  • APD334
  • EoE
  • Eosinophilic oesophagitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an eosinophilic esophagitis (EoE) diagnosis prior to screening and histologically active disease with an esophageal peak eosinophil count (PEC) of ≥ 15 eosinophils per high powered field (eos/hpf)
  • Have dysphagia, defined as solid food going down slowly or getting stuck in the throat with an average frequency of ≥ 2 episodes per week over 2 weeks during the Screening period

Inclusion Criteria for the Extension Treatment Period

  • Completion of the Week 24 study visit [including esophagogastroduodenoscopy (EGD)]
  • Compliance with study procedures during the Double-Blind Treatment Period as assessed by the Investigator
  • No notable safety concerns during the Double-Blind Treatment Period, as determined by the Investigator
  • Willing to comply with all study visits and procedures for the Extension Treatment Period

Exclusion criteria

Exclusion Criteria:

  • History of any of the non-EoE conditions or procedures that may interfere with the evaluation of or affect the histologic (eg eosinophilic gastritis), endoscopic (eg, high-grade esophageal stenosis), or symptom endpoints (eg, esophageal resection) of the study
  • Undergone dilation of an esophageal stricture within 12 weeks prior to Screening EGD
  • Use of for the treatment of EoE within 8 weeks prior to Screening EGD
  • Discontinue, initiate, or change dosing (dosage/frequency) of the following therapies for EoE within 8 weeks prior to Screening EGD. Participants on any of the following therapy need to stay on a stable regimen during study participation:

    1. Elemental diet
    2. EoE food trigger elimination diet
    3. Proton pump inhibitor (PPI) therapy
  • Used any immunotherapy/desensitization including oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) within 12 months prior to the Screening EGD. Note: Stable (ie, ≥ 6 months prior to the Screening EGD) subcutaneous immunotherapy (SCIT) is permitted. Participants on SCIT need to stay on a stable treatment during study participation
  • Used any protocol-specified immunomodulatory therapies within the protocol-specified timeframe prior to Baseline (eg, dupilumab, benralizumab, omalizumab, or infliximab within 12 weeks; a sphingosine-1-phosphate receptor modulator at any time)
  • Use of any agent or device within 12 weeks prior to Baseline
  • Females who are pregnant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Etrasimod Dose 1

    Drug: Etrasimod

  • Experimental
    Etrasimod Dose 2

    Drug: Etrasimod

  • Placebo comparator
    Placebo and Etrasimod

    Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.

    Drug: Placebo · Drug: Etrasimod

Interventions

  • Participants will receive etrasimod tablet by mouth, once daily during the 24-week Double-Blind and 28-week Extension Treatment Periods.

    Also known as: APD334

  • DrugPlacebo

    Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.

  • Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.

    Also known as: APD334

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16

    Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16

    The DSQ was used to measure the frequency and intensity of dysphagia to solid food. DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score = (Sum of points from questions 2+3 in the daily DSQ)×14 days/(Number of diaries reported with non-missing data). DSQ scores can range from 0 to 84, with a higher score indicating worse dysphagia.

    Time frame: Baseline, Week 16

  2. Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16

    Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.

    Time frame: Baseline, Week 16

  3. Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16

    Time frame: Week 16

  4. Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16

    Time frame: Week 16

Other outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AE is defined as an AE that started or worsened in severity on or after the first dose of study treatment. Severity is classified as Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-Threatening, Grade 5: Death Related to AE.

    Time frame: Baseline, up to Week 24

  2. Number of Participants With Serious TEAEs, TEAEs Leading to Study Treatment Discontinuation, TEAEs Leading to Death and TEAEs of Special Interest During 24 Week Double Blind Treatment Period

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 24 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to etrasimod was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

    Time frame: Baseline up to Week 24

07

Results

Posted Oct 26, 2023

Participant flow

The study consisted of a Double-Blind treatment period (24 weeks) and an Open Label Extension (OLE) period (28 weeks). Participants who were in the placebo group during the Double-Blind treatment period were re-randomized to etrasimod 1 milligram (mg) or etrasimod 2 mg at entry into the Open Label Extension period.

Double-Blind Treatment Period (24 Weeks)
Participant flow — Double-Blind Treatment Period (24 Weeks)
MilestoneExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any DoseOLE: Placebo Then Etrasimod 2 mgOLE: Placebo Then Etrasimod 1 mg
Started41392800
Completed30312400
Not completed118400
Withdrew: Adverse event10100
Withdrew: Withdrawal by subject55200
Withdrew: Lost to follow-up21000
Withdrew: Pregnancy01000
Withdrew: Non-compliance20000
Withdrew: Lack of efficacy11100
OLE Period (28 Weeks)
Participant flow — OLE Period (28 Weeks)
MilestoneExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any DoseOLE: Placebo Then Etrasimod 2 mgOLE: Placebo Then Etrasimod 1 mg
Started303101212
Completed212401110
Not completed97012
Withdrew: Non-compliance10001
Withdrew: Other12001
Withdrew: Lack of efficacy21000
Withdrew: Lost to follow-up11000
Withdrew: Withdrawal by subject13000
Withdrew: Adverse event30010

Outcome measures

PrimaryPercent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16

Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.

Time frame:
Baseline, Week 16
Reported as:
Median · Percent change
Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16
Percent changeExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any Dose
Percent Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16-58.4 (-86.21 to -26.25)-39.4 (-71.08 to 78.95)-21.5 (-57.20 to 55.42)
Statistical analysis
  • Experimental: Etrasimod 2 mg vs Placebo Then Etrasimod Any Dose · ANCOVA · p = 0.0103 · Ls mean difference: -18.54 · 95% CI -32.60 to -4.49Estimates were from ANCOVA model for rank score of percent change from baseline in esophageal PEC.
  • Experimental: Etrasimod 1 mg vs Placebo Then Etrasimod Any Dose · ANCOVA · p = 0.2861 · Ls mean difference: -7.53 · 95% CI -21.48 to 6.42Estimates were from ANCOVA model for rank score of percent change from baseline in esophageal PEC.
SecondaryAbsolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16

The DSQ was used to measure the frequency and intensity of dysphagia to solid food. DSQ contained 4 questions, all participants used a diary, and responded to Questions 1 (did you eat solid food) and 2 (did food pass slowly or get stuck). If the participant's answer to Question 2 was 'No', the diary ended for that day. If a participant answered 'Yes', he/she advanced to Questions 3 (did you have to do anything to make the food go down or get relief) and 4 (extent to which the participant experienced pain while swallowing). DSQ score = (Sum of points from questions 2+3 in the daily DSQ)×14 days/(Number of diaries reported with non-missing data). DSQ scores can range from 0 to 84, with a higher score indicating worse dysphagia.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Units on a scale
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16
Units on a scaleExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any Dose
Absolute Change From Baseline in Dysphagia Symptom Questionnaire (DSQ) Score at Week 16-17.11 ± 2.247-14.78 ± 2.166-19.49 ± 2.602
Statistical analysis
  • Experimental: Etrasimod 2 mg vs Placebo Then Etrasimod Any Dose · Linear mixed effects model · p = 0.4894 · Ls mean difference: 2.38 · 95% CI -4.43 to 9.19
  • Experimental: Etrasimod 1 mg vs Placebo Then Etrasimod Any Dose · Linear mixed effects model · p = 0.1671 · Ls mean difference: 4.70 · 95% CI -2.00 to 11.41
SecondaryAbsolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16

Eosinophils was counted in the areas of greatest eosinophil density. Counts were reported as the number of eosinophils/high power field (eos/hpf) and multiple hpfs analyzed until the PEC was clearly identified after taking into account all biopsies from all esophageal levels.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · eos/hpf
Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16
eos/hpfExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any Dose
Absolute Change From Baseline in Esophageal Peak Eosinophil Count (PEC) at Week 16-46.3 ± 17.46-5.7 ± 16.998.3 ± 22.37
Statistical analysis
  • Experimental: Etrasimod 2 mg vs Placebo Then Etrasimod Any Dose · ANCOVA · p = 0.0565 · Ls mean difference: -54.53 · 95% CI -110.59 to 1.54
  • Experimental: Etrasimod 1 mg vs Placebo Then Etrasimod Any Dose · ANCOVA · p = 0.6193 · Ls mean difference: -13.95 · 95% CI -69.61 to 41.71
SecondaryPercentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Percentage of participantsExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any Dose
Percentage Of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than (<) 15 Eosinophils/High Power Field (Eos/Hpf) at Week 1622.012.80
Statistical analysis
  • Experimental: Etrasimod 2 mg vs Placebo Then Etrasimod Any Dose · Mantel Haenszel · p = 0.0007 · Adjusted difference from placebo: 21.90 · 95% CI 9.23 to 34.57
  • Experimental: Etrasimod 1 mg vs Placebo Then Etrasimod Any Dose · Mantel Haenszel · p = 0.0121 · Adjusted difference from placebo: 13.85 · 95% CI 3.03 to 24.66
SecondaryPercentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16
Percentage of participantsExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any Dose
Percentage of Participants With Esophageal Peak Eosinophil Count (PEC) Less Than or Equal to (<=) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 1612.27.70
Statistical analysis
  • Experimental: Etrasimod 2 mg vs Placebo Then Etrasimod Any Dose · Mantel Haenszel · p = 0.0173 · Adjusted difference from placebo: 12.15 · 95% CI 2.15 to 22.16
  • Experimental: Etrasimod 1 mg vs Placebo Then Etrasimod Any Dose · Mantel Haenszel · p = 0.0590 · Adjusted difference from placebo: 8.37 · 95% CI -0.32 to 17.07
Other pre-specifiedNumber of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AE is defined as an AE that started or worsened in severity on or after the first dose of study treatment. Severity is classified as Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-Threatening, Grade 5: Death Related to AE.

Time frame:
Baseline, up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Maximum Severity During 24 Week Double Blind Treatment Period
ParticipantsExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any Dose
TEAE: Grade 119158
TEAE: Grade 291211
TEAE: Grade 3102
TEAE: Grade 4000
TEAE: Grade 5000
Other pre-specifiedNumber of Participants With Serious TEAEs, TEAEs Leading to Study Treatment Discontinuation, TEAEs Leading to Death and TEAEs of Special Interest During 24 Week Double Blind Treatment Period

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 24 weeks after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to etrasimod was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Serious TEAEs, TEAEs Leading to Study Treatment Discontinuation, TEAEs Leading to Death and TEAEs of Special Interest During 24 Week Double Blind Treatment Period
ParticipantsExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any Dose
Serious TEAEs000
TEAEs leading to study treatment discontinuation101
TEAEs leading to death000

Adverse events

Collected over Baseline up to a maximum of 61 weeks (35 days screening period, 24 weeks of double-blind treatment period, 28 weeks of active extended treatment, and 4 weeks of follow-up period). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Etrasimod 2 mg0/41 (0%)0/41 (0%)30/41 (73.2%)
Experimental: Etrasimod 1 mg0/39 (0%)0/39 (0%)27/39 (69.2%)
Placebo Then Etrasimod Any Dose0/28 (0%)0/28 (0%)23/28 (82.1%)
OLE: Etrasimod 2 mg0/30 (0%)0/30 (0%)16/30 (53.3%)
OLE: Etrasimod 1 mg0/31 (0%)0/31 (0%)19/31 (61.3%)
OLE: Placebo Then Etrasimod 2 mg0/12 (0%)0/12 (0%)11/12 (91.7%)
OLE: Placebo Then Etrasimod 1 mg0/12 (0%)1/12 (8.3%)7/12 (58.3%)
Most frequent serious events
Most frequent serious events
EventExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any DoseOLE: Etrasimod 2 mgOLE: Etrasimod 1 mgOLE: Placebo Then Etrasimod 2 mgOLE: Placebo Then Etrasimod 1 mg
Craniocerebral injuryInjury, poisoning and procedural complications0/410/390/280/300/310/121/12
FallInjury, poisoning and procedural complications0/410/390/280/300/310/121/12
Most frequent other events
Showing 10 of 163
Most frequent other events
EventExperimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any DoseOLE: Etrasimod 2 mgOLE: Etrasimod 1 mgOLE: Placebo Then Etrasimod 2 mgOLE: Placebo Then Etrasimod 1 mg
Oesophageal food impactionGastrointestinal disorders1/411/395/280/301/314/120/12
COVID-19Infections and infestations4/414/396/282/305/311/121/12
Hiatus herniaGastrointestinal disorders0/410/391/280/300/310/122/12
HeadacheNervous system disorders3/412/391/281/301/312/120/12
Alanine aminotransferase increasedInvestigations3/412/390/284/300/310/122/12
Aspartate aminotransferase increasedInvestigations1/410/390/280/300/310/122/12
NauseaGastrointestinal disorders6/413/393/282/301/310/120/12
Eosinophilic oesophagitisGastrointestinal disorders0/411/393/281/300/310/120/12
DizzinessNervous system disorders4/414/391/280/301/311/120/12
Abdominal painGastrointestinal disorders2/411/391/281/300/311/120/12

Baseline characteristics

All participants who were randomized to study treatment.

Age, Continuous
Age, Continuous(Years)Experimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any DoseTotal
Mean35.6 ± 9.8039.9 ± 12.8739.1 ± 11.6538.1 ± 11.52
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any DoseTotal
Female20171451
Male21221457
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any DoseTotal
Hispanic or Latino4509
Not Hispanic or Latino36342898
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Etrasimod 2 mgExperimental: Etrasimod 1 mgPlacebo Then Etrasimod Any DoseTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White393828105
More than one race0000
Unknown or Not Reported0000
08

Study locations

256 sites
  • Clinical Research Center of Alabama, LLC
    Birmingham, Alabama 35209, United States
  • GastroHealth - St. Vincent's East
    Birmingham, Alabama 35235, United States
  • Digestive Health Specialists
    Dothan, Alabama 36301, United States
  • Dothan Eyecare - Dr. Brent McKinley (OCT Procedure Only)
    Dothan, Alabama 36301, United States
  • Dothan Surgery Center (Colonoscopy Location)
    Dothan, Alabama 36301, United States
  • Pulmonary Associates (PFT Procedure Only, Second Location )
    Dothan, Alabama 36301, United States
  • Flowers Hospital (PFT Procedure Only)
    Dothan, Alabama 36305, United States
  • Avant Research Associates, LLC
    Huntsville, Alabama 35802, United States
  • Crestwood Medical Center
    Huntsville, Alabama 35802, United States
  • Baily Cove Eye Care
    Huntsville, Alabama 35803, United States
  • Madison Surgery Center
    Madison, Alabama 35758, United States
  • Alabama Eye MD
    Vestavia Hills, Alabama 35216, United States
  • Arizona Retina Institute/ Phoenix Retina Associates(OCT)
    Peoria, Arizona 85381, United States
  • SimonMed Imaging (Imaging)
    Peoria, Arizona 85381, United States
  • Arizona Digestive Health - Sun City
    Sun City, Arizona 85351, United States
  • Sun City Endoscopy Center (Endoscopy)
    Sun City, Arizona 85351, United States
  • Little Rock Eye Clinic
    Little Rock, Arkansas 72205, United States
  • Four Seasons Allergy and Asthma
    Little Rock, Arkansas 72211, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72212, United States
  • Premier Gastroenterology Endoscopy Center
    Little Rock, Arkansas 72212, United States
  • Premier Gastroenterology
    Little Rock, Arkansas 72212, United States
  • Isight Vision Care
    Fountain Valley, California 92708, United States
  • Mile Square Surgery Center
    Fountain Valley, California 92708, United States
  • Pulmonary & Sleep Consultants
    Fountain Valley, California 92708, United States
  • Paragon Rx Clinical, Inc.
    Garden Grove, California 92840, United States
  • Inland Pulmonary Specialists [PFT Only]
    Lake Elsinore, California 92532, United States
  • Advanced Endoscopy and Pain Center - EGD & Biopsy Collection
    Lancaster, California 93534, United States
  • Advanced Endoscopy and Pain Center
    Lancaster, California 93534, United States
  • Antelope Valley Eye Care - OCT
    Lancaster, California 93534, United States
  • Antelope Valley Eye Care
    Lancaster, California 93534, United States
  • Antelope Valley Lung and Sleep Institute
    Lancaster, California 93534, United States
  • Apollo Surgery Center
    Lancaster, California 93534, United States
  • AV Pediatrics, Allergy and Family Medicine - PFT, Physical Exams, Lab Reviews, ECG Reviews
    Lancaster, California 93534, United States
  • Gastro Care Institute
    Lancaster, California 93534, United States
  • Jatinder S. Pruthi, MD FACG CPI - Physical Exams, Lab Reviews, ECG Reviews
    Lancaster, California 93534, United States
  • Om Research LLC
    Lancaster, California 93534, United States
  • Clinical Trials Unit
    Los Angeles, California 90033, United States
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
  • USC IDS Pharmacy
    Los Angeles, California 90033, United States
  • Advanced Vision Care (OCT)
    Los Angeles, California 90067, United States
  • United Surgery Center Murrieta [Endoscopy Only]
    Murrieta, California 92562, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • California Eye Professionals [OCT Only]
    Temecula, California 92591, United States
  • United Surgery Center Temecula [Endoscopy Only]
    Temecula, California 92592, United States
  • RecioMed Clinical Research Network, Inc
    Boynton Beach, Florida 33472, United States
  • Steelgate
    Bradenton, Florida 34203, United States
  • Bay Area Chest Physicians, P.A., - Pulmonary Function Test
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy Center
    Clearwater, Florida 33756, United States
  • West Coast Endoscopy
    Clearwater, Florida 33756, United States
  • MACULA CENTER Dana M. Deupree, M.D., F.A.C.S (OCT)
    Clearwater, Florida 33761, United States
  • Northwood Vision Optical Coherence Tomography (OCT)
    Clearwater, Florida 33761, United States
  • Safety Harbor Surgery Center
    Clearwater, Florida 33761, United States
  • Gastro Florida (Regulatory & Administrative Duties)
    Clearwater, Florida 33762, United States
  • Beraja Medical Institute (OCT)
    Coral Gables, Florida 33134, United States
  • Bayfront Health Seven Rivers (Liver Biopsy Location)
    Crystal River, Florida 34428, United States
  • Citrus Surgery and Endoscopy Center (EGD Location)
    Crystal River, Florida 34429, United States
  • Advanced Eye Center
    Hialeah, Florida 33012, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • West Coast Eye Institute (OCT Procedure Only)
    Inverness, Florida 34452, United States
  • Suncoast Endoscopy Center (EGD Location)
    Inverness, Florida 34453, United States
  • Jupiter Outpatient Surgery Center
    Jupiter, Florida 33458, United States
  • Central Florida Sleep Diagnostic & Treatment Center
    Lakeland, Florida 33812, United States
  • Auzmer Research
    Lakeland, Florida 33813, United States
  • West Coast Eye Institute (OCT Procedure Only)
    Lecanto, Florida 34453, United States
  • The Endoscopy Center (Endoscopy Procedure)
    Miami, Florida 33134, United States
  • Research Associates of South Florida
    Miami, Florida 33137, United States
  • Research Associates of South Florida
    Miami, Florida 33156, United States
  • Juan Barrio, MD (PFT when needed)
    Miami, Florida 33173, United States
  • Florida Eye Specialists and Cataract Institute
    Riverview, Florida 33579, United States
  • Dr. Dennis Bassetti, MD
    Sebring, Florida 33870, United States
  • Highlands Eye Institute, P.A.
    Sebring, Florida 33870, United States
  • The Surgery and Endoscopy Center
    Sebring, Florida 33870, United States
  • Ambulatory Surgery Center
    Tampa, Florida 33613, United States
  • Pulmonology & Sleep Disorders
    Tampa, Florida 33613, United States
  • Day Surgery Center
    Winter Haven, Florida 33884, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Peachtree Allergy and Asthma Clinica - Pulmonary Function Test
    Atlanta, Georgia 30309, United States
  • Piedmont Hospital- DLCO
    Atlanta, Georgia 30309, United States
  • Ross Eyecare - Opthalmoscopy and OCT
    Atlanta, Georgia 30324, United States
  • Georgia Eye Partners
    Decatur, Georgia 30030, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • Atlanta Endoscopy Center LTD
    Decatur, Georgia 30033, United States
  • Pulmonary & Sleep Specialist
    Decatur, Georgia 30033, United States
  • Grand Teton Research Group, PLLC
    Idaho Falls, Idaho 83404, United States
  • Grand Teton Surgical Center
    Idaho Falls, Idaho 83404, United States
  • Idaho Falls Pulmonary/ Sleep and Critical Care Specialists (PFT procedure only)
    Idaho Falls, Idaho 83404, United States
  • Premier Eye Care of Eastern Idaho (OCT procedure only)
    Idaho Falls, Idaho 83404, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Glen Endoscopy Center (Endoscopy Facility)
    Glenview, Illinois 60026, United States
  • GI Alliance (PFT)
    Gurnee, Illinois 60031, United States
  • Illinois Gastroenterology Group-Gurnee (Patients Seen; IP Delivered)
    Gurnee, Illinois 60031, United States
  • Medical Eye Services LTD (Ophthalmoscopy with OCT)
    Gurnee, Illinois 60031, United States
  • North Shore Endoscopy Center (Endoscopy)
    Lake Bluff, Illinois 60044, United States
  • Libertyville Imaging Center (Diagnostic Imaging)
    Libertyville, Illinois 60048, United States
  • Clark Memorial Health (PFTs)
    Jeffersonville, Indiana 47130, United States
  • One Anesthesia, AACC Division
    Jeffersonville, Indiana 47130, United States
  • Baptist Health Floyd (PFTs)
    New Albany, Indiana 47150, United States
  • Gastroenterology Health Partners, PLLC, (IP)
    New Albany, Indiana 47150, United States
  • John Kenyon Eye Center (OCT)
    New Albany, Indiana 47150, United States
  • One Anesthesia, PLLC
    New Albany, Indiana 47150, United States

Showing the first 100 of 256 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Sep 2022, 21 months.

Results were first posted in Oct 2023, 1 year after primary completion.

Of 24 phase 2 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2020
First posted
Dec 24, 2020
StartActual
Dec 15, 2020
Primary completionActual
Sep 30, 2022
CompletionActual
Jun 30, 2023
Results first posted
Oct 26, 2023
Last update
May 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04682639
Lead sponsor
Pfizer
Collaborators
Arena is a wholly owned subsidiary of Pfizer
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Dec 15, 2020
Primary completion
Sep 30, 2022
Completion
Jun 30, 2023
Results posted
Oct 26, 2023
Last update
May 6, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion